(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...

Singapore sovereign wealth fund Temasek plans to deploy another $10 billion in India over the next 2 to 3 years, focusing on ...

Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.

Concerned Islanders and local community organizations have come together to form the Peace Coalition, to sound the alarm that ...

The TikToker was diagnosed with a type of blood cancer known as Myelodysplastic syndrome (MDS), here are the symptoms he ...

The Million Dollar Sellers group convened last week in New York City during and around Amazon’s own Seller Growth Summit ...

This SCD termination deals another blow to Agios' tebapivat prospects following its May 2026 termination in MDS due to efficacy concerns.

A developer’s plans to build 700 apartments across three eight-storey buildings have been met with backlash from residents ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued development in sickle cell disease (SCD), leading the co ...

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, ...

Cellares secures new funding, partnerships and FDA recognition as it prepares for commercial-scale cell therapy manufacturing ...